Potential of Splicing Factor as a Target for Preeclampsia Treatment

Preeclampsia is a serious pregnancy complication characterized by high blood pressure, organ damage, and inadequate blood flow to the fetus. The only definitive cure currently is delivery, but early intervention remains a challenge. Recent research exploring the molecular mechanisms behind preeclampsia has identified a promising target: the splicing factor SRSF5.

A study published in The FASEB Journal investigated the role of SRSF5 in the development of preeclampsia. Using bioinformatics and experimental models, researchers observed that SRSF5 was significantly upregulated in placental tissues from women with preeclampsia. Elevated SRSF5 affects the alternative splicing of the pre-mRNA of MLX, a transcription factor, resulting in a longer, more stable form of MLX. This abnormal MLX interacts with NR2F2, a critical regulator in placental vascular and immune functions, suppressing its activity and leading to placental cell death.

In vivo tests on a mouse model demonstrated that high levels of SRSF5 correlated with preeclampsia-like symptoms, including high blood pressure and proteinuria. Conversely, reducing SRSF5 levels improved placental function and lowered maternal blood pressure. These findings suggest that SRSF5 plays a pivotal role in preeclampsia pathogenesis.

The implications of this research are significant, as targeting SRSF5 or the splicing process could open new therapeutic avenues. Unlike current treatments that only mitigate symptoms, drugs designed to modulate SRSF5 activity may address the root causes of preeclampsia, improving outcomes for mothers and their babies.

This groundbreaking study highlights the importance of molecular research in understanding complex pregnancy disorders and paves the way for potential targeted therapies in the future.

Source: https://medicalxpress.com/news/2025-10-splicing-factor-therapeutic-preeclampsia.html